dc.contributor.author | Geurin, Michael D. | eng |
dc.contributor.author | St. Anna, Leilani | eng |
dc.date.issued | 2010 | eng |
dc.description.abstract | There is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting. (Strength of Recommendation: B, based on a single randomized controlled trial). Effects of TZD therapy on nonglycemic markers of metabolic syndrome are inconsistent compared with the effects of other hypoglycemic medications. | eng |
dc.identifier.uri | http://hdl.handle.net/10355/11924 | eng |
dc.language | English | eng |
dc.publisher | Family Physicians Inquiries Network | eng |
dc.relation.ispartofcollection | Clinical Inquiries, 2010 (MU) | eng |
dc.relation.ispartofcommunity | University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network | eng |
dc.relation.ispartofseries | American family physician, 82, no. 12 (December 2010): [1553]-1554. | eng |
dc.rights | OpenAccess. | eng |
dc.rights.license | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. | eng |
dc.subject | cardiac events | eng |
dc.subject | preventative measures | eng |
dc.subject.lcsh | Cardiovascular emergencies | eng |
dc.title | Thiazolidinedione Therapy for Managing Metabolic Syndrome | eng |
dc.type | Article | eng |